<DOC>
	<DOCNO>NCT00165763</DOCNO>
	<brief_summary>The purpose study examine efficacy safety cholinesterase inhibitor ( donepezil hydrochloride ) Aricept patient vascular dementia ( VaD ) .</brief_summary>
	<brief_title>Efficacy Safety Donepezil Hydrochloride ( Aricept ) Vascular Dementia</brief_title>
	<detailed_description>Vascular dementia significant cause intellectual functional impairment young patient consequent cerebrovascular disease . Post-mortem study show VaD patient cholinergic deficiency like Alzheimer 's disease ( AD ) . Cholinesterase inhibitor standard treatment mild moderate AD . This study aim determine donepezil , cholinesterase inhibitor , would benefit patient VaD decrease score VaDAS-cog improvement CIBIC rating period 24-weeks treatment . Adverse event also monitor .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>The subject eligible study men woman outpatient , age 4060 year old , fulfill criterion VAD accord National Institute Neurological Disorders Stroke Association Internationale pour la Recherche et l'Enseignement en Neurosciences International Workshop ( NINCDSAIREN ) . Subjects shall undergo extensive clinical examination stroke specialist radiological examination ( CT MRI ) document presence cerebrovascular disease . The clinical diagnosis relevant imaging finding . Other Inclusion criterion : Subjects clinically stable hypertension , diabetes mellitus , cardiac disease last 3 month . Subjects history recent stroke , hospitalize stroke previous 3 month . Subjects depression control medication . Subjects hear visual impairment live reliable caregiver . Exclusion criterion : Subjects radiological evidence brain disorder ( subdural hematoma , posttraumatic / postsurgery ) depression psychiatric disorder , infectious disorder , neoplastic condition , metabolic toxic encephalopathy , dementia due AD prior diagnosis AD , major depression psychiatric disorder . Subjects clinical evidence pulmonary , hepatic , gastrointestinal , metabolic , endocrine life threaten disease ; pregnancy , history alcohol drug abuse , sensitivity cholinesterase inhibitor ; use investigational agent , cholinomimetic anticholinergic agent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Vascular Dementia</keyword>
</DOC>